# A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

> **NCT01226732** · PHASE1 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 23 (actual)

## Conditions studied

- Metastatic or Unresectable Solid Tumor Malignancy

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Hsp90 Inhibitor AUY 922

## Key facts

- **NCT ID:** NCT01226732
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-07
- **Final completion:** 2014-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226732, "A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01226732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*